In a Mayo Clinic cohort comprising 82 RARS-T patients, multivariable analysis of thrombosis-free survival revealed that the presence of SF3B1 mutations independently predicted inferior thrombosis-free survival; however, the underlying mechanism involved remains unclear [44]. The gene discussed is SF3B1; the disease is Venous thrombosis.